Search
Close this search box.
Logo Asphalion

Significant Regulatory Update for Medical Device Industry | FDA’s Final Rule on Laboratory Developed Tests (LDTs) Now Effective

July 8, 2024

On May 6th, 2024, the FDA released a pivotal document titled “Final Rule Medical Devices; Laboratory Developed Tests,” marking a transformative moment for the medical device sector. On July 5th, a turning point was achieved since this Final Rule officially came into play.

Defining LDT: A Laboratory Developed Test (LDT) is considered an IVD that is designed, manufactured, and used within a single laboratory.

The FDA has refined its regulations to clarify that LDTs are considered devices under the FD&C Act. This includes scenarios where the IVD’s manufacturer is a laboratory.

Key Takeaways from the Final Rule:

Phaseout Policy: Spanning over 4 years, the policy is structured into 5 distinct stages:

  • Stage 1 (Q2 2025): Adherence to Medical Device Reporting (MDR), correction/removal reporting, and Quality System (QS) requirements (§ 820.198).
  • Stage 2 (Q2 2026): Compliance with registration/listing, labelling, and investigational use prerequisites.
  • Stage 3 (Q2 2027): Fulfilment of QS requirements (Part 820, except § 820.198).
  • Stage 4 (Q4 2027): Premarket review adherence for high-risk IVDs (Class III/licensed under section 351).
  • Stage 5 (Q2 2028): Premarket review adherence for moderate and low-risk IVDs.

 

Scope of Application (section V -Phaseout Policy A.1):

The policy is applicable to IVDs produced and offered as LDTs by laboratories certified under CLIA for high complexity testing and used within such laboratories, even if these IVDs do not align with the FDA’s traditional definition of an LDT (i.e., designed, manufactured, and used within a single laboratory).

Have a look at the final rule: Medical Devices; Laboratory Developed Tests

 

Need help in MedTech? Contact our expert team: info@asphalion.com

Search News & Events

  • Filter by category

Share

Related news and events

ASPHALION | CE Marking

Achieving CE Marking is crucial for medical devices intended for the European market. Asphalion MedTech, a specialized unit within Asphalion, provides comprehensive guidance and expert

WEBINAR | MedTech Regulatory Updates

This webinar will provide a general overview of the main regulatory updates, trends and changes in the global MedTech industry in the first half of

EVENT | Asphalion at Medi’Nov Conference

Last week, Asphalion’s Medical Device Manager Francisco Rodriguez participated at the Medi’Nov Spain Conference with a talk about “The Regulatory Pathway to the Spanish Market”,

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting